Hypertension is the major risk factor for cardiovascular morbidity and mortality. Matter of fact,
untreated hypertension can worsen the overall health, whereas pharmacotherapy can play …

Renal denervation is not a cure for hypertension. Although more recent sham-controlled
trials were positive, a significant minority of patients in each trial were unresponsive. The …

Hypertension is an important risk factor for cardiovascular disease. In the Netherlands, there
are approximately 2.8 million people with hypertension. Despite treatment recommendations …

Herein, we review interventional peripheral neuromodulatory approaches to reduce blood
pressure (BP), specifically focusing on catheter-based renal denervation (RDN), as well as …

Resistant hypertension is diagnosed in patients whose blood pressure target is unmet
despite the use of three or more antihypertensive medications. Systemic sympathetic …

Renal artery denervation has re-emerged as a potential therapeutic option for patients with
hypertension, especially those resistant to conventional pharmacotherapy. This …

Renal artery denervation is achieved by ablating the sympathetic nerves surrounding the
renal arteries using endovascular ultrasound, radiofrequency, or alcohol. Our review article …

Recently, measuring lumen diameter (LD) of renal artery (RA) became relevant with the
introduction of renal denervation (RDN) as a treatment for hypertension. This LD is one of …

Transcatheter renal denervation (RDN) has emerged as a novel treatment option to lower
blood pressure (BP) by ablating the renal nerve. However, inconsistent results of failing to …

Discussion Neuromodulation therapies have been emerging as new options for the CANS;
however, several aspects require attention to enhance the efficacy and accessibility of these …